As of Feb 24
| +0.19 / +0.33%|
The 11 analysts offering 12-month price forecasts for Clovis Oncology Inc have a median target of 53.00, with a high estimate of 86.00 and a low estimate of 36.00. The median estimate represents a -8.46% decrease from the last price of 57.90.
The current consensus among 11 polled investment analysts is to Buy stock in Clovis Oncology Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.